炎症性肠病患者英夫利西单抗降阶治疗后复发的预测因素:基于治疗药物监测策略的价值
在单中心前瞻性IBD数据库中,96例临床和生物学缓解的IBD患者共进行146次英夫利西单抗降阶治疗,1年和2年累积复发概率分别为16%和47%。溃疡性结肠炎与复发风险增加相关(HR=3.2,P=0.005),而英夫利西单抗起始联合治疗(HR=0.39,P=0.0110)和基于谷浓度的降阶治疗(HR=0.45,P=0.024)与复发风险降低相关。
要点
- 英夫利西单抗降阶后1年和2年累积复发概率分别为16%和47%。
- 溃疡性结肠炎与复发风险增加相关(HR=3.2,P=0.005)。
- 起始联合治疗和基于谷浓度的降阶治疗与复发风险降低相关(HR分别为0.39和0.45)。
核心结论
- 使用谷浓度评估降阶治疗的可行性似乎是降低复发风险的前提条件。
研究设计与样本
- 单中心前瞻性IBD数据库研究,纳入临床和生物学缓解且已进行英夫利西单抗降阶治疗的IBD患者,共96例患者进行146次降阶治疗。
主要发现
- 146次降阶治疗中,54次(37%)仅基于临床缓解,92次(63%)基于临床缓解且谷浓度高于7 mg/L。
- 英夫利西单抗降阶后1年和2年累积复发概率分别为16%和47%。
- 溃疡性结肠炎与复发风险增加相关(HR=3.2,P=0.005)。
- 英夫利西单抗起始联合治疗与复发风险降低相关(HR=0.39,P=0.0110)。
- 基于谷浓度的降阶治疗与复发风险降低相关(HR=0.45,P=0.024)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data concerning infliximab drug monitoring during de-escalation of the treatment of inflammatory bowel disease (IBD). AIM: To define the rate and the predictors of relapse following infliximab de-escalation in IBD patients in remission. METHODS: All IBD patients at a single referral centre in clinical and biological remission and in whom the dose of infliximab had been de-escalated were included. Patients in remission with a high trough level of infliximab (>7 mg/L) were considered to be trough level-based de-escalation patients. The data were retrieved from a prospective IBD database. Actuarial analysis was performed for statistical purposes. RESULTS: A total of 146 de-escalations were performed in 96 patients (Crohn's disease/ulcerative colitis: 68%/32%); 54 (37%) were based on clinical remission only, and 92 (63%) were based on clinical remission associated with a trough level above 7 mg/L. The cumulative probabilities of relapse following infliximab de-escalation were 16% and 47% at 1 and 2 years, respectively. Ulcerative colitis was associated with an increased risk of relapse (HR = 3.2, P = 0.005). Conversely, combination therapy at infliximab initiation (HR = 0.39, P = 0.0110) and trough level-based de-escalation were associated with decreased risk of relapse (HR = 0.45, P = 0.024). Trough levels before and after de-escalation were well correlated; a decrease by half was observed following a 2-week interval increase or a half-dose decrease. CONCLUSION: The use of trough levels to assess the feasibility of dose de-escalation seems to be a prerequisite for decreasing the risk of relapse.
引用
- Lucidarme C, Petitcollin A, Brochard C, et al. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Aliment Pharmacol Ther. 2019. PMID: 30589970. doi:10.1111/apt.15046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。